Skip to content

Study · Not a test of the peptide alone · 1987

2 results

Phase II trial of thymosin fraction 5 and thymosin alpha 1.

Dillman RO, Beauregard J, Royston I, Zavanelli MI

Journal of biological response modifiers1 Jun 1987

PMID3598602 (opens in a new tab)PepBankPUB-03598602
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients with colon cancer, non-small-cell lung cancer or hypernephroma given thymosin fraction 5 or thymosin alpha‑1, no tumor responses were observed.

    In plain wordsIn cancer patients given thymosin fraction 5 or thymosin alpha‑1, no tumor responses were seen.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTumor response
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    There were no tumor responses observed in any of these patients
    1 context sentence
    Summary · context
    In this study, 12 patients with colon cancer were treated with thrice weekly thymosin fraction 5 at a dose of 120 mg/m2, and 10 patients with non-small-cell lung cancer received thymosin alpha 1 at 1.2 mg/m2 thrice weekly.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome

    In patients given thymosin fraction 5 or thymosin alpha‑1, immune enhancement was neither obtained nor sustained.

    In plain wordsIn cancer patients given thymosin fraction 5 or thymosin alpha‑1, the immune system was not boosted.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeImmune enhancement
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    immune enhancement was neither obtained nor sustained.
    1 context sentence
    Summary · context
    In this study, 12 patients with colon cancer were treated with thrice weekly thymosin fraction 5 at a dose of 120 mg/m2, and 10 patients with non-small-cell lung cancer received thymosin alpha 1 at 1.2 mg/m2 thrice weekly.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.